CVI Holdings’s Castle Biosciences CSTL Stock Holding History

CVI Holdings’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-37,235	Closed	-$1.4M	–	92
2020 Q2	$1.4M	Buy	+37,235	New	+$1.27M	0.52%	30

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CVI Holdings's CSTL Position: Q3 2020 in Review

CVI Holdings sold out of Castle Biosciences (CSTL) in Q3 2020, closing a stake of 37,235 shares — an estimated $1.4M sold.

CVI Holdings first reported a position in CSTL in Q2 2020 and held it in 1 quarter. The position peaked at $1.4M in Q2 2020. 144 funds tracked by Wall St. Rank hold CSTL as of Q3 2020.

CVI Holdings reported no remaining Castle Biosciences position as of Q3 2020 after selling out during the quarter.
CVI Holdings sold 37,235 Castle Biosciences shares in Q3 2020, an estimated $1.4M.
CVI Holdings first reported a position in Castle Biosciences in Q2 2020 and held it in 1 quarter.
CVI Holdings's Castle Biosciences position peaked at $1.4M in Q2 2020.
144 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2020.

Based on CVI Holdings's 13F filing for Q3 2020, filed 16 Nov 2020.